ArticleAmerican journal of ophthalmology case reports2025
Modified autologous neurosensory retinal transplantation and bevacizumab injection in primary extra-large chronic macular holes.
Article in American journal of ophthalmology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Current Approaches in the Management of Complicated Macular Holes.Turkish journal of ophthalmology · 2026Review
- In vivo imaging of the outer retina after an autologous neurosensory retinal free flap transplantation for a refractory macular hole closure.Journal of medical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the outcome of primary idiopathic extra-large full-thickness macular holes (FTMH) treated with a modified autologous neurosensory retinal transplantation (ART) adjuncted by bevacizumab (BCZ) injection. Methods: In this retrospective interventional case series, five consecutive patients with primary extra-large chronic FTMHs were investigated. The ART procedure included internal limiting membrane (ILM) peeling of both donor and macular hole (MH) areas, placement of the harvested tissue under the edges of MH and use of silicone oil tamponade. Results: The median age was 64 (60-77) years. The first patient developed choroidal neovascularization one month after surgery, which was treated with BCZ injections. Subsequent patients received injection of BCZ (1.25 mg/0.05 mL) into the silicone oil at the end of the initial surgery. At the last follow-up, complete anatomical closure of the MH was achieved in all patients. With the exception of the first patient, all other patients achieved either a final ellipsoid zone (EZ) defect of zero (three cases) or a reduction to 100 μm (one case). The external limiting membrane (ELM) was completely reconstructed in all of patients. All patients demonstrated an improvement in best corrected distant visual acuity (BCDVA) one month after ART surgery, which was sustained throughout the follow-up period (12-42 months). The median LogMAR BCDVA at baseline was 1.4 (1.3-1.4) which decreased to 1.1(1.0-1.1) (P = 0.041) at the first month and 1.0 (0.7-1.2) (P = 0.043) at the last follow-up. Conclusions: The use of ART surgery accompanied by BCZ injection appears to be an effective method for primary extra-large chronic FTMHs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.